311 related articles for article (PubMed ID: 25638260)
1. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
2. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
Front Immunol; 2019; 10():998. PubMed ID: 31156616
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
du Rusquec P; Saint-Jean M; Brocard A; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Immunother; 2014; 37(6):348-50. PubMed ID: 24911795
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
6. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).
Bakacs T; Mehrishi JN; Szabó M; Moss RW
Pharmacol Res; 2012 Aug; 66(2):192-7. PubMed ID: 22503629
[TBL] [Abstract][Full Text] [Related]
7. Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity.
Slavin S; Moss RW; Bakacs T
Pharmacol Res; 2014 Jan; 79():9-12. PubMed ID: 24200897
[TBL] [Abstract][Full Text] [Related]
8. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
10. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
[TBL] [Abstract][Full Text] [Related]
11. Current and Emerging Perspectives on Immunotherapy for Melanoma.
Daud A
Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
[TBL] [Abstract][Full Text] [Related]
12. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
13. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
14. [Antibody therapies for melanoma].
Kiniwa Y; Okuyama R
Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M; Testori A; Ferucci PF
Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
17. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: colitis associated with anti-CTLA-4 therapy.
Gupta A; De Felice KM; Loftus EV; Khanna S
Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
[TBL] [Abstract][Full Text] [Related]
19. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
